DaVita HealthCare Partners (NYSE: DVA) is one of 50 public companies in the “Healthcare Facilities & Services” industry, but how does it compare to its rivals? We will compare DaVita HealthCare Partners to similar companies based on the strength of its profitability, institutional ownership, valuation, dividends, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares DaVita HealthCare Partners and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
DaVita HealthCare Partners $15.01 billion $2.45 billion 9.03
DaVita HealthCare Partners Competitors $5.43 billion $855.44 million 37.07

DaVita HealthCare Partners has higher revenue and earnings than its rivals. DaVita HealthCare Partners is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares DaVita HealthCare Partners and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DaVita HealthCare Partners 8.68% 14.02% 3.78%
DaVita HealthCare Partners Competitors 6.80% 0.40% 0.55%

Insider and Institutional Ownership

83.2% of DaVita HealthCare Partners shares are held by institutional investors. Comparatively, 69.7% of shares of all “Healthcare Facilities & Services” companies are held by institutional investors. 2.1% of DaVita HealthCare Partners shares are held by insiders. Comparatively, 15.4% of shares of all “Healthcare Facilities & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

DaVita HealthCare Partners has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, DaVita HealthCare Partners’ rivals have a beta of 1.01, meaning that their average stock price is 1% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for DaVita HealthCare Partners and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita HealthCare Partners 2 6 1 0 1.89
DaVita HealthCare Partners Competitors 190 1292 1828 32 2.51

DaVita HealthCare Partners currently has a consensus price target of $65.00, suggesting a potential upside of 10.73%. As a group, “Healthcare Facilities & Services” companies have a potential downside of 3.49%. Given DaVita HealthCare Partners’ higher probable upside, analysts clearly believe DaVita HealthCare Partners is more favorable than its rivals.

Summary

DaVita HealthCare Partners beats its rivals on 7 of the 13 factors compared.

About DaVita HealthCare Partners

DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.